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Aim: Strategic Targeting of Registries and International Database of Excellence (STRIDE) is an ongoing,
multicenter registry providing real-world evidence regarding ataluren use in patients with nonsense mu-
tation Duchenne muscular dystrophy (DMD) in clinical practice (NCT02369731). Here, we describe the ini-
tial demographic characteristics of the registry population. Patients & methods: Patients will be followed
up from enrollment for ≥5 years or until study withdrawal. Results & conclusion: As of 9 July 2018, 213
DMD boys were enrolled from 11 countries. Mean (standard deviation) ages at first symptoms and at study
treatment start were 2.7 (1.7) years and 9.8 (3.7) years, respectively. Corticosteroids were used by 190 pa-
tients (89.2%) before data cut-off. Mean (standard deviation) ataluren exposure was 639.0 (362.9) days.
Six patients withdrew. STRIDE is the first drug registry for patients with DMD and represents the largest
real-world registry of patients with nmDMD to date.
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Duchenne muscular dystrophy (DMD) is a rare, progressive, X-linked neuromuscular disorder that occurs in
approximately one in every 3600–5000 live male births [1–3]. It is characterized by progressive muscle degeneration
and weakness due to the absence of functional dystrophin protein [3,4]. Patients with DMD experience functional
decline, loss of ambulation, wheelchair dependency, and ultimately early death due to respiratory or cardiac
failure [2,3]. In approximately 10–15% of boys with DMD, the disorder is caused by a nonsense mutation in the
DMD gene [4–6]. This mutation creates a premature stop codon in the dystrophin mRNA, which prevents the
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production of full-length, functional dystrophin protein [7]. The presence of a nonsense mutation in the DMD
gene should be determined by genetic testing [8].
Ataluren is a first-in-class, orally bioavailable treatment for patients with nonsense mutation DMD (nmDMD),
designed to promote ribosomal readthrough of an in-frame premature stop codon and thereby enable the production
of full-length dystrophin protein [9,10]. Ataluren has been evaluated in patients with nmDMD in two randomized,
double-blind, placebo-controlled trials: one Phase Ib trial [11] and one Phase III trial (Ataluren Confirmatory Trial
in DMD [ACT DMD]) [12]. Both trials showed that ataluren (40 mg/kg/day) had favorable efficacy compared
with placebo in a range of functional end points over 48 weeks, despite not meeting the primary end points [11,12].
In these trials, ataluren was generally well tolerated and the majority of treatment-emergent adverse events (AEs)
were mild to moderate in severity, indicating that ataluren has a favorable benefit–risk profile over a 48-week study
period.
Ataluren is indicated for the treatment of nmDMD in ambulatory patients aged 5 years or older in Brazil, Chile,
Israel, the Republic of Korea and Ukraine, and more recently the indication has expanded to include patients aged
2 years or older in member states of the European Union and Iceland, Liechtenstein and Norway [8]. Efficacy has
not yet been demonstrated in nonambulatory patients [8].
To fulfill a postmarketing commitment to the Pharmacovigilance Risk Assessment Committee of the European
Medicines Agency, and in an effort to generate data on patterns of use and long-term patient outcomes in the setting
of real-world routine clinical practice, an observational registry assessing the safety and effectiveness of ataluren is
currently under way. This registry, the Strategic Targeting of Registries and International Database of Excellence
(STRIDE; ClinicalTrials.gov identifier: NCT02369731), constitutes the first drug registry for patients with DMD.
Here, we describe the initial demographic characteristics of the study population in the STRIDE Registry, as of 9
July 2018.
Patients & methods
Study design
The STRIDE Registry is an ongoing, multicenter, observational, postapproval safety study of ataluren in patients
with nmDMD (ClinicalTrials.gov identifier: NCT02369731). The study is being conducted in countries where
ataluren is available commercially or through an early access program; additional countries may be added as ataluren
becomes more widely accessible. To fulfill regulatory requirements, enrolled patients will be followed up for at
least 5 years from the date of enrollment or until withdrawal from the study or death, whichever occurs first [13].
Patients, who discontinue treatment with ataluren, will continue to be followed up for the duration of the study,
unless they withdraw consent to participate.
No study medication is provided as part of this observational registry study; the treating physician is responsible
for all treatment decisions according to their usual practice and provides prescriptions as appropriate. There are
no standard protocol-mandated procedures or mandated diagnostic tests, although physicians and caregivers are
encouraged to follow published treatment guidelines and standards of care, and nonsense mutations must be
identified by genetic testing at an accredited laboratory [3,8,14,15]. Patients, who do not have a nonsense mutation
in the DMD gene, should not receive ataluren [8].
Ethics
Before any patient is enrolled and study-related data are collected, ethics committee approval of the protocol,
written informed consent form and all patient enrollment materials are obtained in each country and for each site,
as applicable. When appropriate, assent was obtained from the patient. The study is conducted in accordance with
the ethical principles outlined in the Declaration of Helsinki, applicable privacy laws and local regulations for each
participating site, as well as with the Guidelines for Good Pharmacoepidemiology Practices.
Patient eligibility
Patients with a confirmed genetic diagnosis of DMD are eligible to participate in the study if they are, or will
be, receiving usual-care treatment with a commercial supply of ataluren (or receiving care within an early access
program), and are willing to provide written informed consent (by themselves or their parent/legal guardian) for
data-collection procedures.
Patients are excluded from the study if they are receiving ataluren or placebo in an ongoing blinded, randomized
clinical trial, or if they are receiving ataluren in any other ongoing clinical trial or early access program that prevents
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participation in the current study. Patients receiving ataluren in a clinical trial or in an early access program can
become eligible for this study once they have completed the required follow-up and fulfilled the conditions of the
trial or program. Note, patients who are nonambulatory at study entry and are receiving a commercial supply of
ataluren had previously received ataluren in a clinical trial during which they were ambulatory.
Study data
Effectiveness information related to ataluren use (40 mg/kg/day; 10, 10 and 20 mg/kg for morning, mid-day
and evening doses, respectively) in routine clinical care is documented and includes routine clinical assessments
of motor, cardiac and pulmonary function (e.g., timed function tests, North Star Ambulatory Assessment [16],
ambulation as assessed by the 6-min walk test, time to loss of ambulation, frequency of wheelchair use, or use
of other ambulatory-based assistive devices, Performance of Upper Limb scale [17], and cardiac and pulmonary
function assessments). Assessments are performed as per usual clinical care at each center and are not mandatory.
This study is part of the risk-management plan for ataluren; therefore, safety information collected during routine
clinical practice, including AEs, changes in laboratory tests of interest, and information regarding special events
of interest (as per the risk-management plan), is also collected. The safety of ataluren in patients enrolled in
the STRIDE Registry, and effectiveness results for propensity-score matched populations from STRIDE and the
Cooperative International Neuromuscular Research Group Duchenne Natural History Study (CINRG DNHS),
will be presented in a separate publication. Effectiveness data from the STRIDE Registry will be compared with
those from the CINRG DNHS using Kaplan–Meier estimates and Cox regression for motor, pulmonary and
cardiac function outcomes.
Data collection & study methodology
A summary of the STRIDE Registry study design and methodology is shown in Figure 1. At the inclusion visit,
once patients provide their or their parent’s/guardian’s informed consent to be enrolled in the registry, data are
collected, including demographic characteristics, diagnosis information, medical history (e.g., ambulation status,
previous and current exposure to ataluren, and prior and concomitant medications), and clinical information and
symptoms. Loss of ambulation is defined as full-time wheelchair requirement, and prior medications are defined as
any medications that patients ended before study entry. For patients who initiated ataluren as part of a commercial
or early access program before enrollment in the registry, data are obtained retrospectively from their medical records
for the time period between ataluren initiation and enrollment, with appropriate patient/parent/guardian consent
(retrospective visits). Retrospective data from previous clinical trials will not be utilized. Patients enrolled in the
study will continue to be followed up for at least 5 years from the date of enrollment or until withdrawal from the
study, and data will be collected during routine follow-up visits conducted as per usual care, which are estimated
to occur at 3- to 6-month intervals. At each follow-up visit, data will be collected on survival outcomes; status of
ambulation; clinical information, including effectiveness and safety data; current ataluren treatment (e.g., dosing
compliance); and concomitant medications, which are defined as any medications that patients started on or after
the treatment start date. Assessments of musculoskeletal health, rehabilitation, orthopedic and gastrointestinal
management, as well as other measures of psychosocial management, will be collected to allow for comparison of
patient health-management activities in routine clinical care to those of published treatment guidelines. The data
cut-off for inclusion in the present analyses was on 9 July 2018.
Study data are recorded in an electronic data capture system or in paper case-report forms by the treating physician
or designee during a clinic visit or from hospital records, clinical and office charts, and evaluation checklists. All
data are entered via secure web-based data-entry screens and transferred via Secure Sockets Layer connections to
the study database.
Statistical analysis
Originally, the study was intended to enroll approximately 200 patients, and enrollment was to conclude upon entry
of the 200th patient or the completion of the 2-year enrollment period, whichever occurred first. The enrollment
target was chosen for practical and statistical reasons, taking into account the size of the population of patients with
nmDMD in the European Union. The minimum exposure of patients who continue to receive ataluren and who
do not withdraw from the study is 5 years; assuming that the rate of patients lost to follow-up is 2–5% per year,
there would be a minimum of 1000 person-years of exposure to ataluren. The protocol was subsequently amended
to enable enrollment of up to 270 patients because more patients were available for enrollment than expected.
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Retrospective visits
(some patients)
If patients received ataluren
commercially or in an early
access program before
the inclusion visit
Data cut-off
9 July 2018
Follow-up visit(s)
Informed
consent
5-year follow-up
Patients are followed up for at least 5 years from the day they are included
in the study (unless consent is withdrawn)
Inclusion visit
(all patients)
Enrolled in the registry and
signed consent form
Figure 1. Strategic Targeting of Registries and International Database of Excellence Registry postapproval study
design and methodology.
Corticosteroid use was defined as the investigator checking ‘yes’ at any time during the study to the following case
report form question: ‘is the participant currently taking or has ever taken any corticosteroid medication during
the study protocol?’
In general, continuous variables were summarized using descriptive statistics, including the number of patients
(n), mean, standard deviation (SD), 95% CIs, median, minimum and maximum. Categorical variables were
summarized using frequency count as the number and percentage of patients.
Results
Patient disposition
Enrollment of the first patient in the STRIDE Registry occurred on 31 March 2015. As of 9 July 2018, 217 patients
(213 male patients, three female patients and one patient who failed screening) with DMD (Figure 2) from 11
countries with 53 active study sites have been enrolled. The present report details demographic parameters among
male patients who provided informed consent and met eligibility criteria (the evaluable population; n = 213).
Female patients were excluded from this analysis because effectiveness data from patients in this population will
be compared in a separate publication with those from an all-male cohort (CINRG DNHS). Demographics
and characteristics of the female patients are included in Supplementary Table 1. Of the 213 patients in the
evaluable population, nine patients with frameshift mutations were excluded from the effectiveness population
because ataluren is not indicated in these patients) [8]. The number of active countries, number of study sites and
distribution of patients per country are shown in Figure 3.
10.2217/cer-2019-0086 J. Comp. Eﬀ. Res. (Epub ahead of print) future science group
DMD patient demographics from the STRIDE Registry Research Article
Patients who signed the informed
consent form (n = 217)
Patients who were excluded
from the evaluable population (n = 4)
Patients included in the analysis
(evaluable population) (n = 213)
•
•
•
•
Patients who have discontinued the study ‡ (n = 6)
Patients who stopped ataluren or
changed ataluren dose§ (n = 8)
Loss of ambulation (n = 5)
Patients who are still in
the registry (n = 207)
Adverse events (n = 1)
Family’s/patient’s decision (n = 2)
Physician’s decision (n = 2)
Other reasons (n = 3)
Loss to follow-up (n = 1)
Ambulatory patients at study
treatment start (n = 188)
Non-ambulatory patients at
study treatment start (n = 22)
Patients who could not complete
the 10 meter walk or run test
in less than 30 seconds at
treatment start (n = 3)
Patients who lost ambulation
during the study (n = 18)
Failed screening (n = 1)†
Female patient (n = 3)
•
•
•
•
•
•
•
•
Figure 2. Patient disposition.
†Screening failure owing to a frameshift mutation.
‡Patients who withdrew from the study did not necessarily discontinue ataluren treatment.
§No patient changed ataluren dose.
A total of 61 out of 213 patients (28.6%) had participated in previous PTC Therapeutics clinical trials of ataluren
before joining the registry (Table 1). A total of 190 patients (89.2%) received corticosteroids during the study and
before data cut-off, whereas 23 patients (10.8%) had never received corticosteroids.
At the patients’ treatment start date, otherwise known as the first visit captured within the registry, 188 patients
(88.3%) were ambulatory, 22 patients (10.3%) were nonambulatory and three patients (1.4%) could not complete
the 10 meter walk or run test in less than 30 s. Of the 188 patients who were ambulatory at the first visit, 18 (9.6%)
lost ambulation during the study.
Of the 213 enrolled boys, six have withdrawn from the study (n = 5, owing to loss of ambulation; n = 1, lost to
follow-up), and eight have discontinued ataluren but remain in the registry (n = 1, AEs; n = 2, family’s/patient’s
decision; n = 2, physician’s decision; n = 3, other reasons [e.g., the product could no longer be prescribed owing to
local regulations]). Patients who withdrew from the study did not necessarily discontinue ataluren treatment; for
example, the five patients who withdrew owing to loss of ambulation did not discontinue treatment.
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Table 1. Patient demographics and characteristics of male patients enrolled in the Strategic Targeting of Registries and
International Database of Excellence Registry.
Characteristic Patients in the evaluable population (n = 213)
Sex, n (%)
Male 213 (100.0)
Race, n (%)
White 142 (66.7)
Arab/Middle Eastern 6 (2.8)
Arab/Middle Eastern, Asian 1 (0.5)
Asian 5 (2.3)
Mixed race, black/white 1 (0.5)
North African 1 (0.5)
Latin 1 (0.5)
Unknown 54 (0.9)
Weight at first visit† captured within the registry (kg)
n 187
Mean (SD) 30.9 (13.4)
95% CI 29.0, 32.9
Median 26.5
Min, max 13.5, 87.0
Height at first visit† captured within the registry (cm)
n 159
Mean (SD) 124.1 (16.1)
95% CI 121.6, 126.6
Median 121.1
Min, max 94.3, 178.0
BMI at first visit† captured within the registry (kg/m2)
n 159
Mean (SD) 19.0 (4.3)
95% CI 18.4, 19.7
Median 17.9
Min, max 13.7, 40.5
Age at first symptoms (years)
n 195
Mean (SD) 2.7 (1.7)
95% CI 2.4, 2.9
Median 2.5
Min, max 0.0‡, 8.0
Age at muscle biopsy (years)
n 119
Mean (SD) 4.5 (2.5)
95% CI 4.1, 5.0
Median 4.2
Min, max 0.4, 13.0
Time between first symptoms and muscle biopsy (years)
n 112
Mean (SD) 1.6 (1.9)
95% CI 1.3, 2.0
Median 1.1
Min, max -3.4, 8.0
†First visit data are defined as the first data available for each patient, which can either be from a retrospective visit or from the inclusion visit when informed consent was obtained.
‡A minimum age value of zero or a negative minimum age value is due to a prenatal diagnosis.
nmDMD: Nonsense mutation Duchenne muscular dystrophy; SD: Standard deviation.
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Table 1. Patient demographics and characteristics of male patients enrolled in the Strategic Targeting of Registries and
International Database of Excellence Registry (cont.).
Characteristic Patients in the evaluable population (n = 213)
Age at genetic confirmation of nmDMD diagnosis (years)
n 202
Mean (SD) 5.2 (2.9)
95% CI 4.8, 5.6
Median 4.9
Min, max -0.4‡, 15.6
Time between muscle biopsy and genetic confirmation of nmDMD diagnosis (years)
n 119
Mean (SD) 1.0 (2.2)
95% CI 0.6, 1.4
Median 0.3
Min, max -5.0, 12.3
Time between first symptoms and/or laboratory abnormality and genetic confirmation of nmDMD diagnosis (years)
n 186
Mean (SD) 2.4 (2.4)
95% CI 2.0, 2.7
Median 1.7
Min, max -3.4, 12.6
Previously enrolled in ataluren clinical trial, n (%)
No 152 (71.4)
Yes 61 (28.6)
Age at informed consent (years)
n 213
Mean (SD) 10.5 (3.6)
95% CI 10.0, 11.0
Median 10.0
Min, max 5.0, 22.8
Age category at informed consent (years), n (%)
5 0 (0.0)
≥5 213 (100.0)
≥5 to 7 37 (17.4)
≥7 to 10 69 (32.4)
≥10 to 15 81 (38.0)
≥15 26 (12.2)
Age at first visit† captured within the registry (years)
n 213
Mean (SD) 9.8 (3.7)
95% CI 9.3, 10.3
Median 9.0
Min, max 4.0, 22.8
Age category at first visit† captured within the registry (years), n (%)
5 3 (1.4)
≥5 210 (98.6)
≥5 to 7 55 (25.8)
≥7 to 10 62 (29.1)
≥10 to 15 72 (33.8)
≥15 21 (9.9)
†First visit data are defined as the first data available for each patient, which can either be from a retrospective visit or from the inclusion visit when informed consent was obtained.
‡A minimum age value of zero or a negative minimum age value is due to a prenatal diagnosis.
nmDMD: Nonsense mutation Duchenne muscular dystrophy; SD: Standard deviation.
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Table 1. Patient demographics and characteristics of male patients enrolled in the Strategic Targeting of Registries and
International Database of Excellence Registry (cont.).
Characteristic Patients in the evaluable population (n = 213)
Age at cut-off date (years)
n 213
Mean (SD) 11.6 (3.6)
95% CI 11.1, 12.1
Median 11.5
Min, max 5.5, 24.2
†First visit data are defined as the first data available for each patient, which can either be from a retrospective visit or from the inclusion visit when informed consent was obtained.
‡A minimum age value of zero or a negative minimum age value is due to a prenatal diagnosis.
nmDMD: Nonsense mutation Duchenne muscular dystrophy; SD: Standard deviation.
2 4 (1.9)
Number of sites, n   Number of patients, n (%)Country
Austria
Czech Republic
France
Germany
Greece
Hungary
Israel
Italy
Romania
Sweden
United Kingdom
Latvia
Norway
Portugal
Patients in the evaluable
population, as of 9 July 2018
n = 213
6 (2.8)
54 (25.4)
33 (15.5)
1 (0.5)
2 (0.9)
5 (2.3)
49 (23.0)
11 (5.2)
11 (5.2)
37 (17.4)
0 (0.0)
0 (0.0)
0 (0.0)
2
9
1
1
1
1
7
1
1
1
2
11
16
Figure 3. Number of male patients in the registry and study sites by country.
Patient demographics & characteristics
The demographics and characteristics of patients in the study are shown in Table 1. Of the 213 boys in the registry,
the majority were white (142 boys, 66.7%). The mean (SD) weight, height and BMI at informed consent (inclusion
visit) were 30.9 (13.4) kg, 124.1 (16.1) cm and 19.0 (4.3) kg/m2, respectively.
The mean (SD) age at first symptoms, at the time of muscle biopsy and at genetic confirmation of nmDMD
diagnosis was 2.7 (1.7) years, 4.5 (2.5) years and 5.2 (2.9) years, respectively. Of the 213 boys in the registry,
119 (55.9%) had a muscle biopsy. A list of genetically confirmed DMD mutations for patients in the STRIDE
Registry is shown in Supplementary Table 2. There were nine patients whose age at first symptoms was 6 years or
older, which is older than that typically expected for patients with DMD [2]; however, these patients had symptoms
consistent with DMD, and seven of the patients had a stop codon mutation that has previously been identified
and linked to a DMD phenotype (Supplementary Table 3). The mean (SD) times between first symptoms and
muscle biopsy and between muscle biopsy and genetic confirmation of nmDMD diagnosis were 1.6 (1.9) years
and 1.0 (2.2) years, respectively. The mean (SD) time between first symptoms and genetic nmDMD diagnosis was
2.4 (2.4) years.
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The mean age (SD) of patients enrolled in the registry at the inclusion visit was 10.5 (3.6) years. At this time,
the most common age category was ≥10 to <15 years (81/213 patients [38.0%]), and 150 patients (70.4%) were
in the age category of ≥7 to <15 years. Patients first captured in the registry had a mean (SD) age of 9.8 (3.7)
years. The mean (SD) age of patients at the cut-off date of 9 July 2018 was 11.6 (3.6) years.
The most common first clinical signs, symptoms and/or laboratory abnormalities experienced in the lifetime
of the patients, which were reported at the inclusion visit, were elevated creatine kinase (54.0%), delayed walking
(31.9%), difficulty going up stairs (31.0%), difficulty getting up from the floor (Gowers’ sign) (26.8%) and enlarged
calves (pseudohypertrophy) (25.4%) (Supplementary Table 4).
Prior & concomitant medications
Total 48 (22.5%) patients received medications that ended before study entry, which included corticosteroids
(13.1%), vitamin D and vitamin D analogs (3.8%), angiotensin-converting enzyme (ACE) inhibitors (2.3%) and
calcium (1.4%). Of the 213 patients in the registry, 204 (95.8%) are receiving medications that were started on or
after the study entry date (Table 2). These concomitant medications included corticosteroids (67.1%), vitamin D
and vitamin D analogs (53.5%), ACE inhibitors (26.8%), calcium (21.6%), proton pump inhibitors (10.8%) and
osmotic laxatives (6.1%). The concomitant corticosteroids included deflazacort (30.5%), prednisolone (19.7%)
and prednisone (19.7%).
Ataluren use
The 213 patients in the registry used ataluren for a mean (SD) duration of 639.0 (362.9) days or 372.6 patient-years
while enrolled in the registry (Table 3).
Discussion
The STRIDE Registry constitutes the first drug registry for patients with DMD, and was designed to provide
real-world evidence on long-term outcomes for patients with nmDMD receiving ataluren during routine clinical
practice. Here, we have described patient demographics, characteristics and symptoms, as well as ataluren duration
and use of prior and concomitant medications in the STRIDE Registry, as of the cut-off date of 9 July 2018.
Previously, the CARE-NMD project evaluated the care practices for 1062 patients with DMD in seven European
countries using a cross-sectional survey of patients [18]. Patients had a mean (SD) age of 13.0 (7.2) years at
questionnaire completion. Results from this survey showed that the mean (SD) patient age at DMD diagnosis
by muscle biopsy or genetic testing was 4.3 (2.5) years (range of the means across countries, 3.7–6.4 years),
and the mean (SD) time from first symptoms to this diagnosis was 1.3 (1.8) years (range of the means across
countries, 0.8–2.0 years). In the STRIDE Registry, the mean (SD) ages of patients at muscle biopsy and at genetic
diagnosis were 4.5 (2.5) years and 5.2 (2.9) years, respectively; the time from first symptoms to muscle biopsy
and from first symptoms to genetic diagnosis was 1.6 (1.9) years and 2.4 (2.4) years, respectively. Comparisons
of diagnosis times between patients surveyed by the CARE-NMD project and patients in the STRIDE Registry
cannot be made accurately because the CARE-NMD survey included all patients with DMD, the majority of
whom can be readily diagnosed, rather than exclusively patients with nmDMD as in the STRIDE Registry, and
only 71.6% of patients evaluated in CARE-NMD reported having genetic testing for DMD mutations. Moreover,
the proportion of patients from different countries differed between the two studies; the STRIDE Registry included
large proportions of patients from France (25.4%) and Italy (23.0%), whereas, the CARE-NMD project did not
include patients from these countries and included a larger proportion of patients from Germany (39.5%) than did
the STRIDE Registry (15.5%). These differences in demographics could affect the diagnosis results reported owing
to potential differences in clinical practice between countries. Nevertheless, the age at muscle biopsy of patients
in the STRIDE Registry is similar to the age at diagnosis by muscle biopsy or genetic testing of patients surveyed
in the CARE-NMD project. Results from a separate study of 384 patients with DMD in Italy showed that the
mean age at diagnosis for these patients was 3.4 years, and the mean time between first symptoms and diagnosis
was 1.0 years [19]. Of the 382 patients in whom diagnosis of DMD was genetically confirmed, 109 (28.5%) were
genetically diagnosed before muscle biopsy [19]. Therefore, again, these figures cannot be easily compared with
those from the STRIDE Registry, but suggest that patients in the STRIDE Registry are diagnosed later than those
in the total DMD population. Patients with nmDMD in the STRIDE Registry are likely diagnosed later owing
to the sequential genetic testing process for DMD introducing delays in DMD diagnosis. Approximately 80% of
patients with DMD have a deletion or duplication of one or more exons in their DMD gene, and can be identified
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Table 2. Concomitant medications received by male patients enrolled in the Strategic Targeting of Registries and
International Database of Excellence Registry.
Concomitant medication Patients in the evaluable population n = 213
Patients receiving concomitant medications, n (%) 204 (95.8)
Glucocorticoids 143 (67.1)
Deflazacort 65 (30.5)
Prednisolone 42 (19.7)
Prednisone 42 (19.7)
Vitamin D and vitamin D analogs 114 (53.5)
Calcifediol 8 (3.8)
Calcitriol 1 (0.5)
Cholecalciferol 53 (24.9)
Ergocalciferol 5 (2.3)
Vitamin D (not otherwise specified) 48 (22.5)
ACE inhibitors 57 (26.8)
Enalapril maleate 13 (6.1)
Perindopril 15 (7.0)
Perindopril arginine 22 (10.3)
Perindopril erbumine 2 (0.9)
Ramipril 6 (2.8)
Calcium 46 (21.6)
Calcium 24 (11.3)
Calcium carbonate 20 (9.4)
Calcium citrate 1 (0.5)
Calcium phosphate 1 (0.5)
Proton pump inhibitors 23 (10.8)
Esomeprazole magnesium 2 (0.9)
Lansoprazole 6 (2.8)
Omeprazole 12 (5.6)
Omeprazole magnesium 1 (0.5)
Pantoprazole sodium sesquihydrate 1 (0.5)
Rabeprazole sodium 1 (0.5)
Osmotic laxatives 13 (6.1)
Lactitol 1 (0.5)
Macrogol 1 (0.5)
Macrogol 3350; potassium chloride; sodium bicarbonate 2 (0.9)
Macrogol 4000 5 (2.3)
Macrogol; potassium chloride; sodium bicarbonate; sodium chloride 1 (0.5)
Mannitol 1 (0.5)
Potassium; sodium bicarbonate 2 (0.9)
Calcium, combinations with vitamin D and/or other drugs 11 (5.2)
Concomitant medications were coded using the WHO Drug Dictionary (September 2017). Concomitant medications are defined as any medications that patients started on or after the
study treatment start date. Patients may have more than one medication per ATC level three category and preferred term. At each level of patient summarization, a patient is counted
once if the patient reported having one or more medications.
ACE: Angiotensin-converting enzyme; ATC: Anatomical therapeutic chemical.
by multiplex ligation-dependent probe amplification or comparative genome hybridization, the widely available
recommended testing approaches to use first [20]. The remaining approximately 20% of patients without large
deletions or duplications require further genetic testing by Sanger or next-generation sequencing to identify any
small mutations including nonsense mutations. After this, if no mutation is identified, a muscle biopsy is taken
to determine whether dystrophin is absent to exclude other forms of muscular dystrophy. mRNA analysis should
then also be performed to identify any potential intronic mutations, which typically affect <1% of patients with
DMD [20]. The resulting longer diagnostic process for patients with nmDMD highlights a potential unmet need
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Table 3. Duration of ataluren treatment for male patients enrolled in the Strategic Targeting of Registries and
International Database of Excellence Registry.
Treatment duration Patients in the evaluable population n = 213
Ataluren use duration (days†)
n 213
Mean (SD) 639.0 (362.9)
95% CI 590.0, 688.0
Median 617.0
Min, max 5.0, 1453
Ataluren use duration (patient-years‡) 372.6
Categories of ataluren use duration in days, n (%)
1–168 14 (6.6)
169–336 44 (20.7)
337–504 38 (17.8)
505–672 17 (8.0)
673–840 25 (11.7)
841–1008 37 (17.4)
1009–1176 23 (10.8)
1177–1344 12 (5.6)
1345–1512 3 (1.4)
1512 0 (0.0)
†Calculated using the formula: ataluren use duration = (ataluren end date – ataluren start date + 1). The treatment start date is defined as the date of the patient’s first visit in the study,
including ataluren use in retrospective visits. The treatment end date is defined as the last available ataluren stop date or the data cut-off date, whichever occurs first.
‡Calculated by dividing the total ataluren use in days from all evaluable patients by 365.25.
SD: Standard deviation.
for this patient group that should be addressed. However, compared with 5 years ago, next-generation sequencing
is now more accessible and less expensive, meaning that performing the second step in the genetic testing process is
more feasible now than in recent years [21]. It is noteworthy that although guidelines recommend taking a muscle
biopsy only if a genetic diagnosis is inconclusive [20], data from the STRIDE Registry show that a muscle biopsy is
routinely performed before genetic confirmation of DMD.
Importantly, nine of the patients with DMD recruited into the registry carried frameshift mutations, and are
therefore not expected to benefit from ataluren treatment. The initiation of their ataluren treatment by their
treating physician was in error owing to misinterpretation of the genetic laboratory report, which indicated the
presence of a premature stop codon, albeit one arising from a frameshift mutation and not a nonsense mutation.
These patients with frameshift mutations have since stopped receiving ataluren upon guidance from their treating
physician, and will be excluded from the effectiveness analyses. This finding highlights the need for continuous
professional development of the medical care team, especially when there are new personalized medications that
require interpretation of complex genetic information.
As a rare disease, DMD affects relatively few people; there is therefore little documented information on rare
disease epidemiology, particularly for the different genotypic subgroups of patients with DMD, and it is often
difficult to recruit large numbers of patients into clinical trials [22]. Furthermore, patients with rare diseases tend
to have more heterogeneous clinical features than patients with more common diseases [22]. Registries such as the
STRIDE Registry are therefore important for gathering and integrating data on patients with rare diseases, and can
be used for determining real-world outcomes for diverse purposes, including the natural history of a disease and
the effectiveness and safety of therapies.
As a real-world study, STRIDE contains a more heterogeneous population of patients than that in a randomized
clinical trial, which could affect the data collected. For example, the use of corticosteroids in this study (67% at
study entry and 89.2% during the study and before data cut-off ) is less than the 100% use required in the Phase
III ACT DMD trial of ataluren. As a consequence, there will be a wider range of ages and ambulatory ability in the
STRIDE Registry than in clinical trials, making it more difficult to draw conclusions. However, this also means that
data from the STRIDE Registry will be more representative of real-world patients’ experiences. This will therefore
help to progress our understanding of the treatment effects of ataluren and provide real-world data on the care that
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patients receive, as well as more information on nonambulatory patients, who are often omitted from clinical trials.
The collaborative Trajectory Analysis Project, which accesses and analyzes data from patients in natural history
studies [23], and the CINRG DNHS, which was a prospective longitudinal study of patients with DMD followed
between 2006 and 2016 at 23 world-wide centers part of the CINRG academic clinical trial network [24,25], could
be useful for placing real-word data from the STRIDE Registry in context. It is noteworthy that the mean (SD)
ataluren use duration for patients while enrolled in the STRIDE Registry was 639.0 (362.9) days, which is longer
than the 336 days (48 weeks) of ataluren use in each of the Phase IIb and ACT DMD Phase III clinical trials of
ataluren [11,12]. In addition, because some patients were enrolled in the STRIDE Registry after being involved in
a clinical trial of ataluren, the actual mean ataluren use duration for patients in the registry would be longer than
639 days. The STRIDE Registry therefore provides the opportunity to follow-up patients over a longer period than
can be afforded by clinical studies thus far, which are designed to show the benefit of treatment in delaying disease
progression and loss of muscle function. Furthermore, data from the STRIDE Registry will provide additional
characterization and quantification of AEs that may have a low incidence or a long latency period after exposure to
ataluren, or that may be more likely to occur outside the controlled setting of a clinical trial.
Conclusion
In summary, STRIDE constitutes the first drug registry for patients with DMD and represents the largest real-world
study of patients with nmDMD to date. The STRIDE Registry has been established to promote collection of real-
world evidence on ataluren use in patients with nmDMD and improve understanding of the long-term safety and
effectiveness of ataluren. A manuscript describing the safety and real-world effectiveness of ataluren in the STRIDE
Registry, as of the cut-off date of 9 July 2018, will be published separately in due course. In this publication, the
effectiveness of ataluren will be assessed by comparing results from propensity-score-matched patient populations
from the STRIDE Registry and the CINRG DNHS.
Summary points
• Duchenne muscular dystrophy (DMD) is a rare, progressive, genetic, neuromuscular disorder.
• Approximately 10–15% of patients have a nonsense mutation (nm) in the DMD gene coding for the dystrophin
protein.
• Ataluren promotes readthrough of an in-frame premature stop codon, enabling the production of full-length
dystrophin.
• Strategic Targeting of Registries and International Database of Excellence (STRIDE) is the largest real-world study
of patients with nmDMD to date.
• STRIDE is an ongoing registry of patients receiving ataluren in clinical practice.
• As of 9 July 2018, 213 boys have been enrolled in STRIDE from 11 countries.
• Mean age was 2.7 and 5.2 years at first symptoms and at genetic diagnosis, respectively.
• Mean age at first captured visit in STRIDE (treatment start date) was 9.8 years.
• Corticosteroids were used by 190 patients (89.2%) during the study and before data cut-off.
• Total mean exposure to ataluren within the registry was 639.0 days.
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